Volume 21, Number 4NYU Case of the MonthComplexities of Contemporary Bladder Cancer CareNYU Case of the Month, September 2019Richard S Matulewicz[Rev Urol. 2019;21(4):172–174] © 2020 MedReviews®, LLC
Volume 22, Number 1NYU Case of the MonthPrimary Retroperitoneal Lymph Node Dissection for Stage IB Nonseminomatous Germ Cell TumorNYU Case of the Month, April 2020Richard S Matulewicz[Rev Urol. 2020;22(1):40–42] © 2020 MedReviews®, LLC
Volume 22, Number 2Review ArticlesNon–muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative TherapiesTreatment UpdateRichard S MatulewiczGary D SteinbergNon–muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. Risk stratification by American Urological Association (AUA) and European Association of Urology (EAU) guidelines or by using nomograms/risk calculators developed from clinical trial data can help inform patient treatment decisions but may not accurately classify all patients. Risk-adapted adjuvant (post–transurethral resection of bladder tumor [TURBT]) treatment strategies using intravesical therapies are an important means of balancing disease control with potential adverse effects. Adjuvant intravesical instillation with various chemotherapy agents and bacillus Calmette-Guérin (BCG) is well studied and associated with excellent outcomes for most patients. However, upwards of 40% of patients recur within 2 years and roughly 10% progress to muscle-invasive bladder cancer. Novel approaches and agents that aim to reduce the treatment burden associated with NMIBC are increasingly needed. We review the current landscape of NMIBC as it pertains to the use of and rationale for emerging neoadjuvant chemoablative therapies. [Rev Urol. 2020;22(2):43–51] © 2020 MedReviews®, LLCUrothelial carcinomaBacillus Calmette-GuérinNon-muscle invasive bladder cancerMitomycin